Prostate-specific Antigen Density as a Proxy for Predicting Prostate Cancer Severity: Is There Any Difference between Systematic and Targeted Biopsy?

Arafa, Mostafa A; Farhat, Karim Hamda; Rabah, Danny M; Khan, Farrukh K; Mokhtar, Alaa; Al-Taweel, Waleed

Arafa, Mostafa A; Farhat, Karim Hamda; Rabah, Danny M; Khan, Farrukh K; Mokhtar, Alaa; Al-Taweel, Waleed.

Afiliação

Arafa MA; Surgery Department, The Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Farhat KH; Department of Epidemiology, High Institute of Public Health, Alexandria University, Alexandria, Egypt.
Rabah DM; Surgery Department, The Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Khan FK; Surgery Department, The Cancer Research Chair, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Mokhtar A; Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Al-Taweel W; Department of Urology, King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Saudi J Med Med Sci ; 11(4): 299-304, 2023.

Article em En | MEDLINE | ID: mdl-37970462

Palavras-chave

Active surveillance; PSA density; advanced prostate cancer; overdiagnosis; prostate-specific antigen; prostatic neoplasm; screening; systematic biopsy; targeted biopsy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article